Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 2. (a) Geometric mean (%CV)

Published byNele Hauer Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 2. (a) Geometric mean (%CV)"— Presentation transcript:

1 Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot samples at study entry (before starting ledipasvir/sofosbuvir), weeks 1, 2, 4 and 8 of ledipasvir/sofosbuvir treatment and 2, 4, 8 and 12 weeks after completing ledipasvir/sofosbuvir treatment (EOT + 2, EOT + 4, EOT + 8 and EOT + 12). Concentrations of tenofovir diphosphate during ledipasvir/sofosbuvir treatment were compared with entry using a paired t-test. (b) Geometric mean (%CV) tenofovir concentrations (TFV in ng/mL) in plasma samples at study entry (before starting ledipasvir/sofosbuvir), after 8 weeks of ledipasvir/sofosbuvir treatment and 12 weeks after completing ledipasvir/sofosbuvir treatment (EOT + 12). The tenofovir concentrations were 2.1-fold higher at week 8 versus study entry (P = 0.0005). GMR, geometric mean ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 73, Issue 8, 09 May 2018, Pages 2112–2119, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 1. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 1. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot samples at study entry (before starting sofosbuvir + ribavirin), after 12 weeks of sofosbuvir + ribavirin treatment and 12 weeks after completing sofosbuvir + ribavirin treatment (EOT + 12). Concentrations at week 12 of sofosbuvir + ribavirin treatment were compared with entry using a paired t-test. (b) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/million cells) in PBMC samples at study entry (before starting sofosbuvir + ribavirin), after 12 weeks of sofosbuvir + ribavirin treatment and 12 weeks after completing sofosbuvir + ribavirin treatment (EOT + 12). Concentrations at week 12 of sofosbuvir + ribavirin treatment were compared with entry using a paired t-test. (c) Geometric mean (%CV) tenofovir concentrations (TFV in ng/mL) in plasma samples at study entry (before starting sofosbuvir + ribavirin), after 12 weeks of sofosbuvir + ribavirin treatment and 12 weeks after completing sofosbuvir + ribavirin treatment (EOT + 12). The tenofovir concentrations were similar to historical data and unchanged across visits (P = 0.83). GMR, geometric mean ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 73, Issue 8, 09 May 2018, Pages 2112–2119, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 2. (a) Geometric mean (%CV) tenofovir diphosphate concentrations (TFV-DP in fmol/punch) in dried blood spot ... Figure 2. (a) Geometric mean (%CV)"

Similar presentations

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Figure 1. Structure of two poxtA-carrying plasmids in E

Figure 1. Structure of two poxtA-carrying plasmids in E
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1. SpeI-PFGE dendrogram comparing P

Figure 1. SpeI-PFGE dendrogram comparing P
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.
RCTs: randomized controlled ...

RCTs: randomized controlled ...

Similar presentations

Ads by Google